Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25440183 | 0.87 | MAPT (0.78) | MAPTKMT2AHPGDALDH1A1POLB | |
| SCHEMBL25440072 | 0.87 | KMT2A (1.00) | MAPTKMT2AHPGDALDH1A1POLB | |
| SCHEMBL25440299 | 0.85 | KMT2A (0.76) | MAPTKMT2AHPGDALDH1A1POLB | |
| SCHEMBL25440184 | 0.84 | KMT2A (0.74) | MAPTKMT2AHPGDALDH1A1POLB | |
| SCHEMBL30578028 | 0.82 | HPGD (0.69) | MAPTKMT2AHPGDALDH1A1POLB | |
| SCHEMBL25440173 | 0.82 | HPGD (0.69) | MAPTKMT2AHPGDALDH1A1POLB | |
| SCHEMBL30679695 | 0.78 | KMT2A (0.65) | MAPTKMT2AHPGDALDH1A1POLB | |
| SCHEMBL25440265 | 0.78 | KMT2A (0.65) | MAPTKMT2AHPGDALDH1A1POLB | |
| SCHEMBL6164008 | 0.76 | HPGD (0.62) | MAPTKMT2AHPGDALDH1A1POLB | |
| SCHEMBL9196237 | 0.72 | HPGD (0.57) | MAPTKMT2AHPGDALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382840-A1 | ANTI-INFLAMMATORY COMPOUNDS | AMAR SALOMON (US) | 2023-11-30 | — | — | US | claimed |
| CN-103285004-A | Substituted benzoate compositions and application thereof in preparation of anti-tuberculosis drugs | CHINESE PEOPLE S LIBERATION ARMY NO 309 HOSPITAL | 2013-09-11 | — | — | CN | claimed |
| WO-2011066864-A1 | METHOD AND COMPOSITIONS FOR INHIBITION OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2011-06-09 | — | — | WO | claimed |
| US-20230382840-A1 | ANTI-INFLAMMATORY COMPOUNDS | AMAR SALOMON (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382840-A1 | ANTI-INFLAMMATORY COMPOUNDS | AMAR SALOMON (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382840-A1 | ANTI-INFLAMMATORY COMPOUNDS | AMAR SALOMON (US) | 2023-11-30 | — | — | US | disclosed |
| US-11767283-B2 | Anti-inflammatory compounds | AMAR SALOMON (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767283-B2 | Anti-inflammatory compounds | AMAR SALOMON (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767283-B2 | Anti-inflammatory compounds | AMAR SALOMON (US) | 2023-09-26 | — | — | US | disclosed |
| CN-103285004-B | Substituted benzoic acid ester composition and preparing the application in antituberculotics | CHINESE PEOPLE'S LIBERATION ARMY NO.309 HOSPITAL (CN) | 2016-03-30 | — | — | CN | disclosed |
| CN-103285004-A | Substituted benzoate compositions and application thereof in preparation of anti-tuberculosis drugs | CHINESE PEOPLE S LIBERATION ARMY NO 309 HOSPITAL | 2013-09-11 | — | — | CN | disclosed |
| WO-2011066864-A1 | METHOD AND COMPOSITIONS FOR INHIBITION OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011066864-A1 | METHOD AND COMPOSITIONS FOR INHIBITION OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382840-A1 | ANTI-INFLAMMATORY COMPOUNDS | TNF, IL1A, NFKBIA | MAPT 4746/4885KMT2A 786/4885HPGD 343/4885 |
| US-11767283-B2 | Anti-inflammatory compounds | TNF, IL1A, NFKBIA | MAPT 4734/4885KMT2A 815/4885HPGD 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.